SG11201707053SA - Methods of reducing serum levels of fc-containing agents using fcrn antagonsits - Google Patents

Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Info

Publication number
SG11201707053SA
SG11201707053SA SG11201707053SA SG11201707053SA SG11201707053SA SG 11201707053S A SG11201707053S A SG 11201707053SA SG 11201707053S A SG11201707053S A SG 11201707053SA SG 11201707053S A SG11201707053S A SG 11201707053SA SG 11201707053S A SG11201707053S A SG 11201707053SA
Authority
SG
Singapore
Prior art keywords
antagonsits
fcrn
methods
serum levels
containing agents
Prior art date
Application number
SG11201707053SA
Other languages
English (en)
Inventor
Nicolas G H Ongenae
Torsten Dreier
Peter Ulrichts
Haard Johannes De
Christophe Blanchetot
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of SG11201707053SA publication Critical patent/SG11201707053SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201707053SA 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits SG11201707053SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562130076P 2015-03-09 2015-03-09
PCT/IB2016/000398 WO2016142782A1 (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Publications (1)

Publication Number Publication Date
SG11201707053SA true SG11201707053SA (en) 2017-09-28

Family

ID=55863122

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201908259W SG10201908259WA (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
SG11201707053SA SG11201707053SA (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201908259W SG10201908259WA (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Country Status (19)

Country Link
US (1) US20160264669A1 (enExample)
EP (2) EP4006051A1 (enExample)
JP (5) JP2018509413A (enExample)
KR (1) KR102720769B1 (enExample)
AU (2) AU2016230827B2 (enExample)
CA (1) CA2978253A1 (enExample)
DK (1) DK3268391T3 (enExample)
EA (1) EA038178B1 (enExample)
ES (1) ES2882999T3 (enExample)
HU (1) HUE056775T2 (enExample)
IL (2) IL254403B (enExample)
LT (1) LT3268391T (enExample)
MX (2) MX386491B (enExample)
MY (1) MY188761A (enExample)
PL (1) PL3268391T3 (enExample)
PT (1) PT3268391T (enExample)
SG (2) SG10201908259WA (enExample)
WO (1) WO2016142782A1 (enExample)
ZA (1) ZA202109042B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3087095T3 (pl) 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
KR102483016B1 (ko) * 2015-01-30 2023-01-03 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
EP4006051A1 (en) * 2015-03-09 2022-06-01 Argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonists
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
MA50516A (fr) 2017-10-31 2020-09-09 Staten Biotechnology B V Anticorps anti-apoc3 et leurs procédés d'utilisation
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
MX2020013195A (es) 2018-06-08 2021-02-26 Argenx Bvba Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
US20220081481A1 (en) * 2019-01-16 2022-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
MX2021014756A (es) 2019-06-07 2022-01-18 Argenx Bvba Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea.
US20210024620A1 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
TW202140552A (zh) 2020-01-08 2021-11-01 比利時商阿根思公司 用於治療天皰瘡病症的方法
TWI869542B (zh) * 2020-02-10 2025-01-11 大陸商北京拓界生物醫藥科技有限公司 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
US20230220069A1 (en) * 2020-06-17 2023-07-13 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
US20250136699A1 (en) * 2021-08-13 2025-05-01 Jiangsu Biojetay Biotechnology Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
CA3258002A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN BINDING MOLECULES AND METHODS OF USE
JP2025537777A (ja) * 2022-11-14 2025-11-20 アルジェニクス ビーブイ ＦｃＲｎアンタゴニスト分子及びそれらの使用方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
ATE540694T1 (de) 2000-11-20 2012-01-15 Canadian Blood Services Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CN102365297B (zh) * 2009-03-25 2014-10-29 霍夫曼-拉罗奇有限公司 新型抗-α5β1抗体及其应用
AU2012260601B2 (en) * 2011-05-25 2018-02-01 Innate Pharma, S.A. Anti-KIR antibodies for the treatment of inflammatory disorders
EP4530630A3 (en) * 2011-10-26 2025-06-18 Elanco Tiergesundheit AG Monoclonal antibodies and methods of use
US20140302028A1 (en) * 2011-11-18 2014-10-09 Merck Sharp & Dohme Corp. Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
FI3421486T3 (fi) * 2012-06-22 2023-12-15 Dartmouth College Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
PL3087095T3 (pl) * 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
EP4006051A1 (en) * 2015-03-09 2022-06-01 Argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonists

Also Published As

Publication number Publication date
MX386491B (es) 2025-03-18
JP7391132B2 (ja) 2023-12-04
HUE056775T2 (hu) 2022-03-28
DK3268391T3 (da) 2021-09-13
JP2021073282A (ja) 2021-05-13
CA2978253A1 (en) 2016-09-15
ZA202109042B (en) 2025-01-29
MX2017011534A (es) 2018-04-10
JP7403575B2 (ja) 2023-12-22
AU2021277720B2 (en) 2025-03-27
KR20170131463A (ko) 2017-11-29
EP3268391B1 (en) 2021-08-11
JP2024037846A (ja) 2024-03-19
EP3268391A1 (en) 2018-01-17
NZ734416A (en) 2024-12-20
BR112017019191A2 (pt) 2018-05-02
AU2016230827A1 (en) 2017-08-24
JP2022084868A (ja) 2022-06-07
ES2882999T3 (es) 2021-12-03
PL3268391T3 (pl) 2022-01-03
WO2016142782A1 (en) 2016-09-15
LT3268391T (lt) 2021-09-10
EA038178B1 (ru) 2021-07-20
IL295425A (en) 2022-10-01
JP2018509413A (ja) 2018-04-05
EP4006051A1 (en) 2022-06-01
JP2022105084A (ja) 2022-07-12
KR102720769B1 (ko) 2024-10-22
MX2021011633A (es) 2021-10-22
US20160264669A1 (en) 2016-09-15
AU2016230827B2 (en) 2021-10-28
SG10201908259WA (en) 2019-10-30
JP7050191B2 (ja) 2022-04-07
AU2021277720A1 (en) 2021-12-23
MY188761A (en) 2021-12-29
IL254403A0 (en) 2017-11-30
IL254403B (en) 2022-09-01
PT3268391T (pt) 2021-08-19
EA201791984A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
IL254403A0 (en) Methods for lowering the amount of fc-containing substances in the serum by using fcrn antibodies
IL252837B (en) fcrn antibodies and methods of using them
LT3368688T (lt) Kompozicijos ir būdai, skirti modifikuotų citozinų nustatymui sekvenavimu
PL3201361T3 (pl) Sposoby ilościowego oznaczania pozakomórkowego DNA
HUE065780T2 (hu) FCRN ellenanyagok és eljárások alkalmazásukra
EP3297661A4 (en) Method of improving characteristics of proteins
GB201515557D0 (en) Method of sequencing
GB201515558D0 (en) Method of sequencing
IL249729A0 (en) Methods and materials for cleaning proteins
IL254765A0 (en) A method for the monomerization of recombinant antibody molecules
PL3189336T3 (pl) Sposób określania ryzyka stanu przedrzucawkowego
IL255094A0 (en) A method for increasing the percentage of multimeric strains for a monomeric dsfv-fab antibody
GB201522552D0 (en) Method of improving adhesion
GB201604627D0 (en) Improved method of FT-IMS
IL252712A0 (en) Method for protein production
SG11201800894SA (en) Method for parallel quantification of protein variant
GB201512602D0 (en) Method of modelling biomarkers
TH1601002706A (th) แอนทิบอดีที่จำเพาะต่อ FcRn
GB201611950D0 (en) Construction panel and method for its manufacture
GB201503485D0 (en) Methods & Kits
TH1601000293A (th) วิธีสำหรับควบคุมระดับฟิวโคสิเลชันในโปรตีน